Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

As the Omicron variant spreads rapidly, India is ramping up it's arsenal against Covid-19. Here is what you need to know about Serum Institute manufactured Covovax-:

It is a protein-based Covid-19 vaccine developed by Novavax in the US
In August Novavax had given SII the licence to manufacture and supply the vaccine 
The WHO has already cleared it and it has an Emergency Use Authorization (EUA)
Covovax has reported an efficacy of over 89% during it's clinical trial. 
Covovax targets the spike protein on the surface of the SARS-CoV-2 coronavirus
Once a person is given a shot of this vaccine, the body is expected to recognise these copies of the spike proteins as a foreign substance and build immunity against them. 
Different from Covishield which uses a separate virus to carry the weakened spike protein to trigger an immunity response 


Covovax Explained: Adding another weapon to the Covid arsenal 

Covovax is Serum Institute of India's version of the protein-based Covid-19 vaccine developed by Novavax, headquartered in US

EJ Explains: What is Covovax and how is it different from other shots

Covovax is Serum Institute of India's version of the protein-based Covid-19 vaccine developed by Novavax, headquartered in US

As the Omicron variant spreads rapidly, India is ramping up it's arsenal against Covid-19. Here is what you need to know about Serum Institute manufactured Covovax-:
Also watch |&nbsp;<a title="Covid-19: India clears 2 new vaccines - Corbevax &amp; Covovax - and one oral pill" href="https://www.editorji.com/india-news/covid-19-india-clears-2-new-vaccines-corbevax-covovax-and-one-oral-pill-1640675924598">Covid-19: India clears 2 new vaccines - Corbevax &amp; Covovax - and one oral pill</a>
<ul>
<li>It is a protein-based&nbsp;Covid-19&nbsp;vaccine developed by Novavax&nbsp;in the US In August&nbsp;Novavax had given SII the licence to manufacture and supply the vaccine</li>
<li>The WHO has already cleared it and it has an Emergency Use Authorization (EUA)</li>
<li>Covovax&nbsp;has reported an efficacy of over 89% during it's clinical trial.&nbsp;</li>
<li>Covovax targets the spike protein on the surface of the SARS-CoV-2&nbsp;coronavirus</li>
<li>Once a person is given a shot of this vaccine, the body is expected to recognise these copies of the spike proteins as a foreign substance and build immunity against them.&nbsp;</li>
<li>Different from Covishield&nbsp;which uses a separate virus to carry the weakened spike protein to trigger an immunity response&nbsp;</li>
</ul>

World Health Organization has issued an emergency use listing for Covovax, a Covid-19 vaccine manufactured by Serum Institute of India. 
The vaccine is produced under licence from Novavax and is part of the COVAX facility portfolio, giving a much-needed boost to ongoing efforts to vaccinate more people in lower-income countries.
A statement by WHO said that it assessed Covovax based on the review of data on quality, safety and efficacy, a risk management plan, programmatic suitability, and manufacturing site inspections carried out by the Drugs Controller General of India.
The statement also said that the vaccine meets WHO standards for protection against Covid-19, its benefit far outweighs any risks, and that the vaccine can be used globally.
Serum Institute CEO Adar Poonwalla while tweeting the news said that the vaccine showed great safety and efficacy. 

Covovax, Serum Institute manufactured Covid-19 vaccine gets WHO nod

World Health Organization has issued an emergency use listing for Covovax, a Covid-19 vaccine manufactured by Serum Institute of India. 

SII-manufactured Covovax&nbsp;gets WHO's&nbsp;approval for emergency use SII&nbsp;produces&nbsp;Covovax&nbsp;under licence from Novavax
WHO: benefits to Covovax&nbsp;far outweight&nbsp;any risks WHO: vaccines meets our standards for protection against Covid-19

The vaccine is produced under licence from Novavax and is part of the COVAX facility portfolio, giving a much-needed boost to ongoing efforts to vaccinate more people in lower-income countries.

World Health Organization has issued an emergency use listing for Covovax, a Covid-19 vaccine manufactured by Serum Institute of India.&nbsp;
The vaccine is produced under licence from Novavax and is part of the COVAX facility portfolio, giving a much-needed boost to ongoing efforts to vaccinate more people in lower-income countries.
A statement by WHO said that it assessed&nbsp;Covovax&nbsp;based on the review of data on quality, safety and efficacy, a risk management plan, programmatic suitability, and manufacturing site inspections carried out by the Drugs Controller General of India.
Also watch:&nbsp;<a href="https://www.editorji.com/coronavirus/amid-omicron-fears-who-warns-against-vaccine-hoarding-by-rich-countries-1639115223267">Amid Omicron fears, WHO warns against vaccine hoarding by rich countries</a>
The statement also said that the vaccine meets WHO standards for protection against Covid-19, its&nbsp;benefit far outweighs any risks, and that the vaccine can be used globally.
Serum Institute CEO&nbsp;Adar Poonwalla&nbsp;while tweeting the news said that the vaccine showed great safety and efficacy.&nbsp;

In setback to Serum Institute of India, a panel of the central drug authority has denied permission for the phase 2/3 trial of Covid-19 vaccine Covovax on children aged two to 17 years, PTI has reported quoting sources.
The SII applied to the Drugs Controller General of India on Monday seeking permission for conducting a trial of Covovax on 920 children, 460 each in the 12-17 and 2-11 age groups, at 10 sites.
"The Subject Expert Committee on Covid-19 of the Central Drugs Standard Control Organisation noted that the vaccine has not been approved in any country," the report said.
The panel has also asked Serum to submit the safety and immunogenicity data of Covovax from the ongoing clinical trial in adults for considering the conduct of a clinical trial in children.
The clinical trials of Covovax began in India in March and the SII hopes to launch it by September for adults.
&nbsp;

Serum denied permission for Covid vaccine Covovax trials on children 

An expert&nbsp; panel has denied permission to Serum Institute for phase 2/3 trial of Covid-19 vaccine Covovax on children aged two to 17 years

In setback to Serum Institute of India, the central drug authority has denied permission for the phase 2/3 trial of Covid-19 vaccine Covovax on children aged two to 17 years, PTI has reported quoting sources.
The SII applied to the Drugs Controller General of India on Monday seeking permission for conducting a trial of Covovax on 920 children, 460 each in the 12-17 and 2-11 age groups, at 10 sites.
"The Subject Expert Committee on Covid-19 of the Central Drugs Standard Control Organisation noted that the vaccine has not been approved in any country," the report said.
The panel has also asked Serum to submit the safety and immunogenicity data of Covovax from the ongoing clinical trial in adults for considering the conduct of a clinical trial in children.
The clinical trials of Covovax began in India in March and the SII hopes to launch it by September for adults.
&nbsp;

In setback to Serum Institute of India, a panel of the central drug authority has denied permission for the phase 2/3 trial of Covid-19 vaccine Covovax on children aged two to 17 years

In setback to Serum Institute of India, a panel of the central drug authority has denied permission for the phase 2/3 trial of Covid-19 vaccine Covovax on children aged two to 17 years, PTI has reported quoting sources.
The SII applied to the Drugs Controller General of India on Monday seeking permission for conducting a trial of Covovax on 920 children, 460 each in the 12-17 and 2-11 age groups, at 10 sites.
"The Subject Expert Committee on Covid-19 of the Central Drugs Standard Control Organisation noted that the vaccine has not been approved in any country," the report said.
The panel has also asked Serum to submit the safety and immunogenicity data of Covovax from the ongoing clinical trial in adults for considering the conduct of a clinical trial in children.
The clinical trials of Covovax began in India in March and the SII hopes to launch it by September for adults.
&nbsp;

SII readying 1 billion doses of 5 Covid-19 vaccines

Serum Institute of India will have 1 billion doses of 5 different Covid-19 vaccines by the end of 2021-22: Adar Poonawalla

Serum Institute readying 1 bn doses of 5 Covid&nbsp;vaccines
Vaccine doses to be ready before the end of 2021-22
SII&nbsp;CEO: plan to launch 1 vaccine every quarter
SII&nbsp;also manufacturing Oxford's Covishield&nbsp;vaccine
Covisheild&nbsp;expected to be out in first quarter of 2021

The Serum Institute of India (SII) is readying one billion doses of five different vaccines against Covid-19, across the world before the end of 2021-22, a report has said. Adar Poonawalla, CEO of the world&rsquo;s largest vaccine maker by volume, said his company plans to launch at least one vaccine every quarter likely by the beginning of next year. These will include Covishield, Covovax, COVIVAXX, COVI-VAC, and SII COVAX. Covishield, which is being developed by Oxford University in collaboration with drug-maker AstraZeneca, is currently undergoing Phase 3 of clinical trials in India among nearly 1,600 people. Serum Institute of India has partnered with AstraZeneca to manufacture the vaccine candidate, which is expected to be launched in the first quarter of 2021 and immunisation is expected to start by January if clearances are given early.

covovax

Categories